WASHINGTON — The Biden administration has agreed to delay for a year the implementation of one of President Trump’s signature drug pricing policies.
The policy at issue would prevent drug makers and middlemen from negotiating rebates on prescription drugs. The prohibition was scheduled to go into effect in January 2022, but the Biden administration agreed to delay it until 2023, a court order filed Saturday showed. District Court Judge John Bates gave the Biden team until April 1 to decide whether it wants to continue defending the policy.
The Pharmaceutical Care Management Association, which represents drug middlemen in Washington, sued to stop the rule.
About the Author Reprints
